$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

$nwbo Overview Financials Valuation SEC Filings Company Website

2017 Form 10-K Financial Statement

#000114420418020971 Filed on April 17, 2018

Income Statement

Concept	2017	2016 Q4	2016
Revenue	$336.0K	$70.00K	$623.0K
YoY Change	-46.07%	-91.89%	-64.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$21.50M	$4.490M	$19.81M
YoY Change	8.54%	-39.65%	-20.46%
% of Gross Profit
Research & Development	$33.52M	$16.83M	$60.08M
YoY Change	-44.22%	-62.44%	-41.74%
% of Gross Profit
Depreciation & Amortization	$400.0K	$50.00K	$189.0K
YoY Change	111.64%	150.0%	237.5%
% of Gross Profit
Operating Expenses	$33.52M	$21.32M	$60.08M
YoY Change	-44.22%	-59.2%	-41.74%
Operating Profit	-$54.68M		-$79.27M
YoY Change	-31.02%		-37.23%
Interest Expense	$5.545M	-$3.060M	$3.818M
YoY Change	45.23%	-111.2%	-8.07%
% of Operating Profit
Other Income/Expense, Net	-$18.47M	$0.00	-$1.457M
YoY Change	1167.33%	-100.0%
Pretax Income	-$73.14M	-$30.71M	-$80.21M
YoY Change	-8.82%	27.53%	-30.09%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$73.14M	-$30.71M	-$80.21M
YoY Change	-8.82%	27.54%	-30.09%
Net Earnings / Revenue	-21768.75%	-43871.43%	-12875.44%
Basic Earnings Per Share
Diluted Earnings Per Share	-$301.2K	-$240.3K	-$722.1K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2017	2016 Q4	2016
SHORT-TERM ASSETS
Cash & Short-Term Investments	$117.0K	$6.190M	$6.186M
YoY Change	-98.11%	-71.62%	-71.64%
Cash & Equivalents	$117.0K	$6.871M	$6.186M
Short-Term Investments
Other Short-Term Assets	$1.285M	$1.700M	$1.698M
YoY Change	-24.32%	-25.76%	-25.79%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.402M	$7.884M	$7.884M
YoY Change	-82.22%	-67.29%	-67.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$47.49M	$315.0K	$44.87M
YoY Change	5.83%	-33.82%	-2.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$17.00K	$148.0K	$148.0K
YoY Change	-88.51%	-22.11%	-72.54%
Total Long-Term Assets	$47.51M	$45.02M	$45.02M
YoY Change	5.52%	-3.58%	-3.58%
TOTAL ASSETS
Total Short-Term Assets	$1.402M	$7.884M	$7.884M
Total Long-Term Assets	$47.51M	$45.02M	$45.02M
Total Assets	$48.91M	$52.91M	$52.91M
YoY Change	-7.56%	-25.27%	-25.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.40M	$12.38M	$35.73M
YoY Change	-48.5%	5.61%	108.03%
Accrued Expenses		$901.0K	$901.0K
YoY Change		-31.17%	-31.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$2.760M	$2.760M
YoY Change	-100.0%	196.77%	195.5%
Long-Term Debt Due	$19.60M	$20.75M	$20.75M
YoY Change	-5.53%	83.14%	83.17%
Total Short-Term Liabilities	$87.68M	$76.41M	$76.41M
YoY Change	14.76%	17.93%	17.67%
LONG-TERM LIABILITIES
Long-Term Debt	$8.517M	$3.000M	$3.000M
YoY Change	183.9%	-71.54%	-71.55%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$8.517M	$3.000M	$3.000M
YoY Change	183.9%	-71.55%	-71.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$87.68M	$76.41M	$76.41M
Total Long-Term Liabilities	$8.517M	$3.000M	$3.000M
Total Liabilities	$96.20M	$79.41M	$79.41M
YoY Change	21.15%	5.21%	5.21%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock		$687.1M
YoY Change		8.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$47.29M	-$26.50M	-$26.50M
YoY Change
Total Liabilities & Shareholders Equity	$48.91M	$52.91M	$52.91M
YoY Change	-7.56%	-25.27%	-25.27%

Cashflow Statement

Concept	2017	2016 Q4	2016
OPERATING ACTIVITIES
Net Income	-$73.14M	-$30.71M	-$80.21M
YoY Change	-8.82%	27.54%	-30.09%
Depreciation, Depletion And Amortization	$400.0K	$50.00K	$189.0K
YoY Change	111.64%	150.0%	237.5%
Cash From Operating Activities	-$36.50M	-$14.09M	-$55.65M
YoY Change	-34.42%	-39.35%	-29.2%
INVESTING ACTIVITIES
Capital Expenditures	-$8.000K	-$170.0K	-$4.939M
YoY Change	-99.84%	-93.8%	-26.84%
Acquisitions
YoY Change
Other Investing Activities	$220.0K
YoY Change
Cash From Investing Activities	$212.0K	-$170.0K	-$4.939M
YoY Change	-104.29%	-93.8%	-26.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	34.29M	17.49M	$38.31M
YoY Change	-10.49%	-57.72%	-59.35%
NET CHANGE
Cash From Operating Activities	-36.50M	-14.09M	-$55.65M
Cash From Investing Activities	212.0K	-170.0K	-$4.939M
Cash From Financing Activities	34.29M	17.49M	$38.31M
Net Change In Cash	-$6.754M	3.230M	-$16.18M
YoY Change	-58.25%	-79.03%	-282.19%
FREE CASH FLOW
Cash From Operating Activities	-$36.50M	-$14.09M	-$55.65M
Capital Expenditures	-$8.000K	-$170.0K	-$4.939M
Free Cash Flow	-$36.49M	-$13.92M	-$50.71M
YoY Change	-28.05%	-32.06%	-29.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6186000	USD
CY2017Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	0	USD
CY2016Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	685000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1285000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1013000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	1402000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	7884000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	169000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	315000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	148000	USD
CY2016Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	45022000	USD
CY2017Q4	us-gaap	Assets Assets	48907000	USD
CY2016Q4	us-gaap	Assets Assets	52906000	USD
CY2017Q4	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	6200000	USD
CY2016Q4	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	6200000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	76405000	USD
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8517000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	96200000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	157000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	686972000	USD
CY2017Q4	nwbo	Development Stage Enterprise Deficit Accumulated During Development Stage1 DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage1	788619000	USD
CY2016Q4	nwbo	Development Stage Enterprise Deficit Accumulated During Development Stage1 DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage1	715476000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-597000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1848000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-26499000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52906000	USD
CY2016Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	44559000	USD
CY2016Q4	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	5200000	USD
CY2017Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1121000	USD
CY2016Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	310000	USD
CY2017Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	2507000	USD
CY2016Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	3000000	USD
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	623000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60081000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10867000	USD
CY2016	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	79889000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-79266000	USD
CY2016	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	17891000	USD
CY2016	us-gaap	Interest Expense InterestExpense	3818000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-80214000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-6732000	USD
CY2016	nwbo	Adjustment To Additional Paidup Capital Extinguishment Of Derivate Liability AdjustmentToAdditionalPaidupCapitalExtinguishmentOfDerivateLiability	10131000	USD
CY2016	nwbo	Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest	3021000	USD
CY2016	nwbo	Stock Issued During Period Value Conversion Of Accounts Payable To Common Stock StockIssuedDuringPeriodValueConversionOfAccountsPayableToCommonStock	28000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33515000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-54678000	USD
CY2017	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2578000	USD
CY2017	us-gaap	Interest Expense InterestExpense	5545000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-73143000	USD
CY2017	nwbo	Deemed Dividend Related To Warrant Modification DeemedDividendRelatedToWarrantModification	0	USD
CY2016	nwbo	Deemed Dividend Related To Warrant Modification DeemedDividendRelatedToWarrantModification	5647000	USD
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1152000	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-12569000	USD
CY2017	us-gaap	Legal Fees LegalFees	9041000	USD
CY2016	us-gaap	Legal Fees LegalFees	8941000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-74409000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-85861000	USD
CY2017	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
CY2016	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-5680000	USD
CY2017	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	2297000	USD
CY2016	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1457000	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	242849000	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	111078000	shares
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1971000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	2445000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-78243000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-75588000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1971000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1877000	USD
CY2016	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	19987000	USD
CY2016	nwbo	Value Of Warrants Exercised For Cash ValueOfWarrantsExercisedForCash	8066000	USD
CY2016	nwbo	Adjustments To Additional Paid In Capital Modification On Warrant Exercise Price AdjustmentsToAdditionalPaidInCapitalModificationOnWarrantExercisePrice	5647000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	5647000	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	127000	USD
CY2016	nwbo	Adjustments To Additional Paid In Capitaloffering Cost Related To Warrants Exercise AdjustmentsToAdditionalPaidInCapitalofferingCostRelatedToWarrantsExercise	795000	USD
CY2016	nwbo	Stock And Warrants Issued During Period Value Private Placement Net Of Offering Costs StockAndWarrantsIssuedDuringPeriodValuePrivatePlacementNetOfOfferingCosts	2206000	USD
CY2016	nwbo	Adjustments To Additional Paid In Capital Reclassification AdjustmentsToAdditionalPaidInCapitalReclassification	1872000	USD
CY2016	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	0	USD
CY2016	nwbo	Adjustment To Additional Paidup Capital Extinguishment Of Shares Payable AdjustmentToAdditionalPaidupCapitalExtinguishmentOfSharesPayable	22539000	USD
CY2016	nwbo	Share Payments Due To Related Parties Value SharePaymentsDueToRelatedPartiesValue	8885000	USD
CY2017	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	281000	USD
CY2016	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1037000	USD
CY2017	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	501000	USD
CY2016	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	17899000	USD
CY2017	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	7704000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55652000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36495000	USD
CY2016	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	4939000	USD
CY2017	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	8000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.56
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.25
CY2016	nwbo	Extinguishment Of Shares Payable ExtinguishmentOfSharesPayable	22539000	USD
CY2017	nwbo	Extinguishment Of Derivative Liabilities ExtinguishmentOfDerivativeLiabilities	0	USD
CY2016	nwbo	Extinguishment Of Derivative Liabilities ExtinguishmentOfDerivativeLiabilities	10131000	USD
CY2017	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2016	us-gaap	Stock Issued1 StockIssued1	28000	USD
CY2017	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	521000	USD
CY2016	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	488000	USD
CY2017	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	2162000	USD
CY2016	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	825000	USD
CY2017	nwbo	Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise ReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise	3054000	USD
CY2016	nwbo	Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise ReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise	0	USD
CY2017	us-gaap	Notes Assumed1 NotesAssumed1	0	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4939000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	212000	USD
CY2016	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-366000	USD
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	189000	USD
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	439000	USD
CY2017	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	-131000	USD
CY2016	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	-42000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34290000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38308000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-4761000	USD
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	6106000	USD
CY2017	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	9509000	USD
CY2016	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	19987000	USD
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	856000	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1077000	USD
CY2017	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2117000	USD
CY2016	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	6417000	USD
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1516000	USD
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	850000	USD
CY2017	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	28593000	USD
CY2016	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	5218000	USD
CY2017	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	2805000	USD
CY2016	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	260000	USD
CY2017	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1994000	USD
CY2016	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6871000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23048000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117000	USD
CY2017	nwbo	Return Of Common Stock And Warrants ReturnOfCommonStockAndWarrants	0	USD
CY2016	nwbo	Return Of Common Stock And Warrants ReturnOfCommonStockAndWarrants	8000	USD
CY2017	nwbo	Extinguishment Of Shares Payable ExtinguishmentOfSharesPayable	0	USD
CY2016	us-gaap	Notes Assumed1 NotesAssumed1	310000	USD
CY2017	nwbo	Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterest	11979000	USD
CY2016	nwbo	Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterest	0	USD
CY2017Q4	nwbo	Current Assets Less Payables CurrentAssetsLessPayables	86300000	USD
CY2017Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	5400000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	700000	USD
CY2017Q4	us-gaap	Accrued Environmental Loss Contingencies Noncurrent AccruedEnvironmentalLossContingenciesNoncurrent	6200000	USD
CY2017	us-gaap	Site Contingency Loss Exposure In Excess Of Accrual Best Estimate SiteContingencyLossExposureInExcessOfAccrualBestEstimate	6200000	USD
CY2016	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	10131000	USD
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales	415000	USD
CY2016	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Warrant Granted FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisWarrantGranted	5317000	USD
CY2016	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Related To Sharesettled Debt FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRelatedToSharesettledDebt	5680000	USD
CY2016	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Related To Conversion Of Sharesettled Debt FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRelatedToConversionOfSharesettledDebt	480000	USD
CY2016	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-17891000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	559000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	405000	USD
CY2017	us-gaap	Depreciation Depreciation	439000	USD
CY2016	us-gaap	Depreciation Depreciation	189000	USD
CY2017Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	31375000	USD
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	31429000	USD
CY2017	us-gaap	Interest Expense Other InterestExpenseOther	11000	USD
CY2016	us-gaap	Interest Expense Other InterestExpenseOther	6000	USD
CY2017	us-gaap	Interest Expense Debt InterestExpenseDebt	5545000	USD
CY2016	us-gaap	Interest Expense Debt InterestExpenseDebt	3818000	USD
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	520027000	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	77024000	shares
CY2016Q2	nwbo	Stock Outstanding Percentage Limit StockOutstandingPercentageLimit	0.2	pure
CY2016Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	22500000	USD
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	27267	shares
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	58278	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	320406	shares
CY2016	nwbo	Class Of Warrant Or Right Granted In Registered Direct Offering ClassOfWarrantOrRightGrantedInRegisteredDirectOffering	14485	shares
CY2016	nwbo	Number Of Warrants Granted To Cognate NumberOfWarrantsGrantedToCognate	35504	shares
CY2016	nwbo	Class Of Warrant Or Rightnon Cognate Warrants Cancelled ClassOfWarrantOrRightnonCognateWarrantsCancelled	37147	shares
CY2017	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	24558	shares
CY2016	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	1761	shares
CY2016	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	15357	shares
CY2017	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	59483	shares
CY2015Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	4.4
CY2016Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	1.78
CY2017Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	0.5
CY2016	nwbo	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	0.43
CY2016	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	0.53
CY2016	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	9.36
CY2016	nwbo	Class Of Warrant Or Right Granted In Registerd Direct Offering Weighted Average Exercise Price ClassOfWarrantOrRightGrantedInRegisterdDirectOfferingWeightedAverageExercisePrice	2.7
CY2016	nwbo	Class Of Warrants Or Rights Granted To Congnate Weighted Average Exercise Price ClassOfWarrantsOrRightsGrantedToCongnateWeightedAverageExercisePrice	0.69
CY2016	nwbo	Class Of Warrant Or Right To Cognate Cancelled Weighted Average Exercise Price ClassOfWarrantOrRightToCognateCancelledWeightedAverageExercisePrice	0.35
CY2017	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	0.11
CY2017	nwbo	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	0.36
CY2017	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	1.4
CY2016	nwbo	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	35287	shares
CY2017	nwbo	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	362240	shares
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
CY2012Q3	nwbo	Office Space Taken Under Lease Agreement OfficeSpaceTakenUnderLeaseAgreement	7,097
CY2016Q1	nwbo	Office Space Taken Under Lease Agreement OfficeSpaceTakenUnderLeaseAgreement	505
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	153415000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	204106000	USD
CY2017Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	15426000	USD
CY2016Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	14911000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	9814000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	17106000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	178655000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	236123000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	178655000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	236123000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	153400000	USD
CY2017Q4	nwbo	Deferred Tax Assets Tax Credit Carry Forward Unused Research And Development DeferredTaxAssetsTaxCreditCarryForwardUnusedResearchAndDevelopment	15400000	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.04	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.018	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.007	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.028	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.786	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.222	pure
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.004	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.023	pure
CY2017	nwbo	Effective Income Tax Rate Reconciliation Deduction Cancellation Of Warrants EffectiveIncomeTaxRateReconciliationDeductionCancellationOfWarrants	0.002	pure
CY2016	nwbo	Effective Income Tax Rate Reconciliation Deduction Cancellation Of Warrants EffectiveIncomeTaxRateReconciliationDeductionCancellationOfWarrants	-0.166	pure
CY2017	nwbo	Effective Income Tax Rate Reconciliation Deduction Cancellation Of Shares EffectiveIncomeTaxRateReconciliationDeductionCancellationOfShares	-0.002	pure
CY2016	nwbo	Effective Income Tax Rate Reconciliation Deduction Cancellation Of Shares EffectiveIncomeTaxRateReconciliationDeductionCancellationOfShares	-0.078	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.086	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.027	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.012	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.076	pure
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-59454000	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-11160000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	2911000	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1427000	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-57467000	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-17776000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-924000	USD
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-5189000	USD
CY2017Q4	us-gaap	Notes Payable Current NotesPayableCurrent	7122000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2450000	USD
CY2017Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	135000	USD
CY2016Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	10960000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	13015000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	13239000	USD
CY2017Q4	nwbo	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	5385000	USD
CY2016Q4	nwbo	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	23393000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	40171000	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4862000	USD
CY2017Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	11226000	USD
CY2016Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	9791000	USD
CY2017Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	6010000	USD
CY2016Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2017Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	40000000	shares
CY2016Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	40000000	shares
CY2017	nwbo	Proceeds From Issuance Of Common Stock And Debt ProceedsFromIssuanceOfCommonStockAndDebt	39500000	USD
CY2017	us-gaap	Debt Instrument Increase Decrease For Period Net DebtInstrumentIncreaseDecreaseForPeriodNet	5000000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	328900000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	328900000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	157000000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	157000000	shares
CY2017	nwbo	Trade Liabilities Waived By Related Parties Amount TradeLiabilitiesWaivedByRelatedPartiesAmount	3750000	USD
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply, and the fair value of environmental remediation liabilities.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-1.070	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0	pure
CY2017Q4	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2017Q4	nwbo	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Amount EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsAmount	78300000	USD
CY2017Q4	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	78300000	USD
CY2016	nwbo	Deemed Dividend On Convertible Preferred Stock DeemedDividendOnConvertiblePreferredStock	0	USD
CY2017	nwbo	Deemed Dividend On Convertible Preferred Stock DeemedDividendOnConvertiblePreferredStock	1266000	USD
CY2017Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	479000	USD
CY2017Q2	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	496000	USD
CY2017Q4	us-gaap	Area Of Land AreaOfLand	275000	acre
CY2017Q4	us-gaap	Lessor Operating Lease Variable Lease Payment Terms And Conditions LessorOperatingLeaseVariableLeasePaymentTermsAndConditions	The tenant will undertake at least $1.1 million of repairs and improvements to the building in return for five and a half months of free rent (which began upon execution of the lease and ends on March 24, 2018). Thereafter, the tenant will pay rent at an annualized rate of approximately $1.0 million for the first year, and thereafter rent at an annualized rate of approximately $1.4 million for each year or partial year for the rest of the lease term, plus VAT. The tenant will also pay a proportional share of the common costs and the insurance costs for the overall site.
CY2017Q4	us-gaap	Lessor Leasing Arrangements Operating Leases Term Of Contract LessorLeasingArrangementsOperatingLeasesTermOfContract	P5Y
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1111000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	503000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1644000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-4676000	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2017	nwbo	Increasedecrease In Deferred Tax Assets IncreasedecreaseInDeferredTaxAssets	78300000	USD
CY2017	nwbo	Adjustments To Additional Paid In Capital Beneficial Conversion Feature Of Series Convertible Preferred Stock AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOfSeriesConvertiblePreferredStock	276000	USD
CY2017	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	The Tax Act also permits an indefinite carry forward of net operating losses generated in taxable years ending after December 31, 2017, subject to a utilization limitation of 80% of taxable income.
CY2017	nwbo	Adjustments To Additional Paid In Capital Beneficial Conversion Feature Of Series B Convertible Preferred Stock AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOfSeriesBConvertiblePreferredStock	366000	USD
CY2017	nwbo	Stock Issued During Period Value Conversion Of Convertible Preferred Stock StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock	680000	USD
CY2017	nwbo	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptionsestimated Foreiture Rate SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsestimatedForeitureRate	0	pure
CY2017	nwbo	Adjustments To Additional Paid In Capitaldeemed Dividends Related To Conversion Of Preferred Convertible Stock Into Common Stock AdjustmentsToAdditionalPaidInCapitaldeemedDividendsRelatedToConversionOfPreferredConvertibleStockIntoCommonStock	-624000	USD
CY2017	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2540000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	856000	USD
CY2017	nwbo	Stock And Warrants Issued During Period Value Private Placement Net Of Offering Costs StockAndWarrantsIssuedDuringPeriodValuePrivatePlacementNetOfOfferingCosts	983000	USD
CY2017	nwbo	Value Of Warrants Exercised For Cash ValueOfWarrantsExercisedForCash	2866000	USD
CY2017	nwbo	Adjustments To Additional Paid In Capitaloffering Cost Related To Warrants Exercise AdjustmentsToAdditionalPaidInCapitalofferingCostRelatedToWarrantsExercise	229000	USD
CY2017	nwbo	Adjustments To Additional Paid In Capital Reclassification AdjustmentsToAdditionalPaidInCapitalReclassification	2162000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2445000	USD
CY2017	nwbo	Stock Issued During Period Value Issued For Non Cash Consideration StockIssuedDuringPeriodValueIssuedForNonCashConsideration	0	USD
CY2017	nwbo	Adjustments To Additional Paid In Capital Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise	3054000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	3750000	USD
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1892000	USD
CY2017	nwbo	Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest	15640000	USD
CY2017	nwbo	Stock Issued During Period Value Extinguishment Of Senior Convertible Notes StockIssuedDuringPeriodValueExtinguishmentOfSeniorConvertibleNotes	2054000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	842000	USD
CY2017Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	2608000	USD
CY2017Q4	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	3308000	USD
CY2017Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	46087000	USD
CY2016Q4	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	5200000	USD
CY2016Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	10062000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1551	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	11343	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	238	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12656	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	7964	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	9.90
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.32
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1.38
CY2017	nwbo	Adjustments To Additional Paid In Capitaldeemed Dividends Related To Accretion Of Redemption Value Of Series Convertible Stock AdjustmentsToAdditionalPaidInCapitaldeemedDividendsRelatedToAccretionOfRedemptionValueOfSeriesConvertibleStock	-276000	USD
CY2017	nwbo	Adjustments To Additional Paid In Capitaldeemed Dividends Related To Accretion Of Redemption Value Of Series B Convertible Stock AdjustmentsToAdditionalPaidInCapitaldeemedDividendsRelatedToAccretionOfRedemptionValueOfSeriesBConvertibleStock	-366000	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y10M24D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y
CY2017	nwbo	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P4Y6M
CY2015Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	27982000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	10062000	USD
CY2017	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Warrant Granted FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisWarrantGranted	41557000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	728000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	720000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	4262000	USD
CY2017	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	-5264000	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-3054000	USD
CY2017	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Related To Conversion Of Sharesettled Debt FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRelatedToConversionOfSharesettledDebt	1892000	USD
CY2017	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	2578000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	46087000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.25
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y9M18D
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.96	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.02	pure
CY2017	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	8395000	USD
CY2016	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	0	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	842000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	127000	USD
CY2017	nwbo	Stock And Warrants Issued To Related Party Expenses StockAndWarrantsIssuedToRelatedPartyExpenses	0	USD
CY2016	nwbo	Stock And Warrants Issued To Related Party Expenses StockAndWarrantsIssuedToRelatedPartyExpenses	13654000	USD
CY2017	us-gaap	Paid In Kind Interest PaidInKindInterest	407000	USD
CY2016	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2017	nwbo	Refund Of Leashold Improvement Related To Uk Construction RefundOfLeasholdImprovementRelatedToUkConstruction	-220000	USD
CY2016	nwbo	Refund Of Leashold Improvement Related To Uk Construction RefundOfLeasholdImprovementRelatedToUkConstruction	0	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2866000	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	8066000	USD
CY2017	nwbo	Payment Of Warrants Excercise Offering Cost PaymentOfWarrantsExcerciseOfferingCost	229000	USD
CY2016	nwbo	Payment Of Warrants Excercise Offering Cost PaymentOfWarrantsExcerciseOfferingCost	795000	USD
CY2017	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	9564000	USD
CY2016	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5450000	USD
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1604000	USD
CY2016	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2017	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	3258000	USD
CY2016	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6754000	USD
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16177000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	47000	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2909000	USD
CY2017Q4	nwbo	Fair Value Of Embedded Conversion Option FairValueOfEmbeddedConversionOption	2608000	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	355000	USD
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P5Y
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.5	pure
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	50% will vest over a 24-month period in equal monthly installments, provided that the recipient continues to be employed by the Company. The unvested portions of the Options are subject to accelerated vesting upon (i) a change of effective control of the Company, (ii) the filing of the first Biologics License Application or other application for product approval in any jurisdiction, (iii) completion of any randomized clinical trial that meets its endpoint(s) (Phase II or Phase III), (iv) decision by the Board, in its discretion or (v) the death of the recipient.
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	200000	USD
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	800000	USD
CY2017	nwbo	Deemed Dividends Related To Accretion Of Redemption Value Of Series Convertible Stock DeemedDividendsRelatedToAccretionOfRedemptionValueOfSeriesConvertibleStock	276000	USD
CY2016	nwbo	Deemed Dividends Related To Accretion Of Redemption Value Of Series Convertible Stock DeemedDividendsRelatedToAccretionOfRedemptionValueOfSeriesConvertibleStock	0	USD
CY2017	nwbo	Deemed Dividends Related To Accretion Of Redemption Value Of Series B Convertible Stock DeemedDividendsRelatedToAccretionOfRedemptionValueOfSeriesBConvertibleStock	366000	USD
CY2016	nwbo	Deemed Dividends Related To Accretion Of Redemption Value Of Series B Convertible Stock DeemedDividendsRelatedToAccretionOfRedemptionValueOfSeriesBConvertibleStock	0	USD
CY2017	nwbo	Deemed Dividends On Conversion Of Series Convertible Preferred Stock To Common Stock DeemedDividendsOnConversionOfSeriesConvertiblePreferredStockToCommonStock	624000	USD
CY2016	nwbo	Deemed Dividends On Conversion Of Series Convertible Preferred Stock To Common Stock DeemedDividendsOnConversionOfSeriesConvertiblePreferredStockToCommonStock	0	USD
CY2017	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1892000	USD
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2017	us-gaap	Notes Issued1 NotesIssued1	1826000	USD
CY2016	us-gaap	Notes Issued1 NotesIssued1	0	USD
CY2017	nwbo	Stock Issued During Period Value For Warrant Cashless Exercise StockIssuedDuringPeriodValueForWarrantCashlessExercise	7000	USD
CY2016	nwbo	Stock Issued During Period Value For Warrant Cashless Exercise StockIssuedDuringPeriodValueForWarrantCashlessExercise	0	USD
CY2017	nwbo	Issuance Of Warrants In Conjunction With Note Payable IssuanceOfWarrantsInConjunctionWithNotePayable	139000	USD
CY2016	nwbo	Issuance Of Warrants In Conjunction With Note Payable IssuanceOfWarrantsInConjunctionWithNotePayable	0	USD
CY2017	us-gaap	Notes Reduction NotesReduction	3750000	USD
CY2016	us-gaap	Notes Reduction NotesReduction	0	USD
CY2017	nwbo	Offering Costs Payable OfferingCostsPayable	0	USD
CY2016	nwbo	Offering Costs Payable OfferingCostsPayable	800000	USD
CY2017	nwbo	Issuance Of Common Stock In Connection Conversion Of Notes Payable IssuanceOfCommonStockInConnectionConversionOfNotesPayable	0	USD
CY2016	nwbo	Issuance Of Common Stock In Connection Conversion Of Notes Payable IssuanceOfCommonStockInConnectionConversionOfNotesPayable	1869000	USD
CY2016Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	32561000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	850000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	31711000	USD
CY2017Q4	us-gaap	Notes Payable NotesPayable	135000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.25
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	13600000	USD
CY2017	nwbo	Loss On Extinguishment Of Debt LossOnExtinguishmentOfDebt	12119000	USD
CY2016	nwbo	Loss On Extinguishment Of Debt LossOnExtinguishmentOfDebt	1152000	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales	2162000	USD
CY2017	nwbo	Number Of Warrants Warrants Exercised On Cashless Basis NumberOfWarrantsWarrantsExercisedOnCashlessBasis	16071	shares
CY2017	nwbo	Weighted Average Exercise Pricewarrants Exercised On Cashless Basis WeightedAverageExercisePricewarrantsExercisedOnCashlessBasis	0.20
CY2016Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	732	USD
CY2015	nwbo	Class Of Warrant Or Right Oustanding Remaining Contractual Term ClassOfWarrantOrRightOustandingRemainingContractualTerm	P2Y8M12D
CY2016	nwbo	Class Of Warrant Or Right Oustanding Remaining Contractual Term ClassOfWarrantOrRightOustandingRemainingContractualTerm	P3Y10M10D
CY2017	nwbo	Class Of Warrant Or Right Oustanding Remaining Contractual Term ClassOfWarrantOrRightOustandingRemainingContractualTerm	P2Y7M13D
CY2017Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7500000	USD
CY2017Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	18800000	shares
CY2017Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.26
CY2017Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	414000	USD

Files In Submission

Name	View Source	Status
0001144204-18-020971-index-headers.html	Edgar Link	pending
0001144204-18-020971-index.html	Edgar Link	pending
0001144204-18-020971.txt	Edgar Link	pending
0001144204-18-020971-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nwbo-20171231.xml	Edgar Link	completed
nwbo-20171231.xsd	Edgar Link	pending
nwbo-20171231_cal.xml	Edgar Link	unprocessable
nwbo-20171231_def.xml	Edgar Link	unprocessable
nwbo-20171231_lab.xml	Edgar Link	unprocessable
nwbo-20171231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv491101_10k.htm	Edgar Link	pending
tv491101_ex10-69.htm	Edgar Link	pending
tv491101_ex10-69img1.jpg	Edgar Link	pending
tv491101_ex21-1.htm	Edgar Link	pending
tv491101_ex23-1.htm	Edgar Link	pending
tv491101_ex31-1.htm	Edgar Link	pending
tv491101_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2017 Form 10-K Financial Statement

#000114420418020971 Filed on April 17, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2017 Form 10-K Financial Statement

#000114420418020971 Filed on April 17, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo